Premium
Capped antithrombin III dosing is cost effective in the management of asparaginase‐associated thrombosis
Author(s) -
Young Jennifer,
Sawyer Jaclyn,
Jenkins Meredith,
O'Brien Maureen,
LuchtmanJones Lori,
Breese Erin H.
Publication year - 2019
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.27719
Subject(s) - medicine , dosing , antithrombin , asparaginase , thrombosis , heparin , population , pharmacology , intensive care medicine , surgery , lymphoblastic leukemia , environmental health , leukemia
Asparaginase therapy induces a transient antithrombin III (ATIII) deficiency, which contributes to the risk of asparaginase‐induced thrombosis. At Cincinnati Children's Hospital Medical Center, management of asparaginase‐induced thrombosis includes ATIII supplementation during therapeutic anticoagulation with enoxaparin. Due to the expense associated with ATIII, a capped dosing approach for ATIII was evaluated in this population. Peak ATIII levels were obtained following capped doses to evaluate response. In this pilot evaluation, 11 patients received a total of 138 capped doses for a total cost savings of $803 782. This pilot evaluation represents the first reported analysis of capped ATIII dosing in oncology patients.